Assessment of the effectiveness and safety of ethosuximide in the treatment of abdominal pain related to irritable bowel syndrome - IBSET: protocol of a randomised, parallel, controlled, double-blind and multicentre trial

Nicolas Kerckhove, Julien Scanzi, Bruno Pereira, Denis Ardid, Michel Dapoigny, Nicolas Kerckhove, Julien Scanzi, Bruno Pereira, Denis Ardid, Michel Dapoigny

Abstract

Introduction: Irritable bowel syndrome (IBS) is characterised by the association of abdominal chronic pain with bowel habit disorders in the absence of identifiable organic disease. This is the first reason for consultation in gastroenterology, with an estimated prevalence of 10%-15% in industrialised countries. Although this is a benign gastrointestinal disease, its chronicity profoundly impacts the patient's quality of life and causes considerable health spending. Actual medical treatments are poorly efficient on IBS-related abdominal pain, making it a major public health concern. The mechanisms causing IBS symptoms are unknown. Recent studies have shown the involvement of T-type channel in abdominal pain. We aim to evaluate the therapeutic potential of ethosuximide, a T-type channel blocker, on the abdominal pain of patients presenting an IBS.

Methods and analysis: The IBSET trial is a randomised, controlled, parallel, double-blind and multicentre study. It is the first clinical trial evaluating the efficacy and safety of ethosuximide on abdominal pain related to IBS. Adults with IBS that report significant abdominal pain (≥4/10) at least for 3 months will be included. 290 patients will be randomly assigned to receive either ethosuximide or placebo over 12 weeks after 1 week of run-in period. The primary endpoint is the rate of responders (pain reduction ≥30% and Subject Global Assessment of Relief score ≥4). The intensity of abdominal pain will be assessed by an 11-point Numerical Rating Scale before and after 12 weeks of treatment and the score of the Subject Global Assessment of Relief scale at the end of treatment. The secondary endpoints are the safety of ethosuximide, the intensity and features of IBS and quality of life.

Ethics and dissemination: The study was approved by an independent medical ethics committee (CPP Sud-Est VI, Clermont-Ferrand, France). The results will be published in a peer-review journal and presented at international congresses.

Trial registration number: NCT02973542; Pre-results.

Keywords: ethosuximide; ibs; t-type calcium channel.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Figures

Figure 1
Figure 1
Study design overview. CE, clinic exam; ICF, inform and consent form; IC/EC, inclusion/exclusion criteria; LB, logbook; Q, questionnaires; SE, side effect; TTT, treatment.

References

    1. Thompson WG. Irritable bowel syndrome: a management strategy. Baillieres Best Pract Res Clin Gastroenterol 1999;13:453–60. 10.1053/bega.1999.0039
    1. Drossman DA, Chang L, Bellamy N, et al. . Severity in irritable bowel syndrome: a Rome Foundation Working Team report. Am J Gastroenterol 2011. 1760;106:1749–59. 10.1038/ajg.2011.201
    1. Müller-Lissner SA, Bollani S, Brummer RJ, et al. . Epidemiological aspects of irritable bowel syndrome in Europe and North America. Digestion 2001;64:200–4. 10.1159/000048862
    1. Dapoigny M, Bellanger J, Bonaz B, et al. . Irritable bowel syndrome in France: a common, debilitating and costly disorder. Eur J Gastroenterol Hepatol 2004;16:995–1001.
    1. Mönnikes H. Quality of life in patients with irritable bowel syndrome. J Clin Gastroenterol 2011;45:S98–S101. 10.1097/MCG.0b013e31821fbf44
    1. Longstreth GF, Thompson WG, Chey WD, et al. . Functional bowel disorders. Gastroenterology 2006;130:1480–91. 10.1053/j.gastro.2005.11.061
    1. Piche T, Ducrotté P, Sabate JM, et al. . Impact of functional bowel symptoms on quality of life and fatigue in quiescent Crohn disease and irritable bowel syndrome. Neurogastroenterol Motil 2010;22:626–e174. 10.1111/j.1365-2982.2010.01502.x
    1. Brun-Strang C, Dapoigny M, Lafuma A, et al. . Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study. Eur J Gastroenterol Hepatol 2007;19:1097–103. 10.1097/MEG.0b013e3282f1621b
    1. Piche T, Saint-Paul MC, Dainese R, et al. . Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 2008;57:468–73. 10.1136/gut.2007.127068
    1. Piche T, Barbara G, Aubert P, et al. . Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009;58:196–201. 10.1136/gut.2007.140806
    1. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973;14:125–32. 10.1136/gut.14.2.125
    1. Whitehead WE. Patient subgroups in irritable bowel syndrome that can be defined by symptom evaluation and physical examination. Am J Med 1999;107:33–40. 10.1016/S0002-9343(99)00078-9
    1. Azpiroz F, Bouin M, Camilleri M, et al. . Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil 2007;19:62–88. 10.1111/j.1365-2982.2006.00875.x
    1. Akbar A, Yiangou Y, Facer P, et al. . Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut 2010;59:767–74. 10.1136/gut.2009.194449
    1. Cervero F, Laird JM. Role of ion channels in mechanisms controlling gastrointestinal pain pathways. Curr Opin Pharmacol 2003;3:608–12. 10.1016/j.coph.2003.06.007
    1. Wood JD. Neuropathy in the brain-in-the-gut. Eur J Gastroenterol Hepatol 2000;12:597–600. 10.1097/00042737-200012060-00002
    1. Todorovic SM, Jevtovic-Todorovic V. The role of T-type calcium channels in peripheral and central pain processing. CNS Neurol Disord Drug Targets 2006;5:639–53. 10.2174/187152706779025490
    1. Sekiguchi F, Kawabata A. T-type calcium channels: functional regulation and implication in pain signaling. J Pharmacol Sci 2013;122:244–50. 10.1254/jphs.13R05CP
    1. Scanzi J, Accarie A, Muller E, et al. . Colonic overexpression of the T-type calcium channel Cav 3.2 in a mouse model of visceral hypersensitivity and in irritable bowel syndrome patients. Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc (Published Online First: 15 May 2016). 10.1111/nmo.12860
    1. Marger F, Gelot A, Alloui A, et al. . T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome. Proc Natl Acad Sci U S A 2011;108:11268–73. 10.1073/pnas.1100869108
    1. Todorovic SM, Jevtovic-Todorovic V. Neuropathic pain: role for presynaptic T-type channels in nociceptive signaling. Pflugers Arch 2013;465:921–7. 10.1007/s00424-012-1211-y
    1. Hamidi GA, Ramezani MH, Arani MN, et al. . Ethosuximide reduces allodynia and hyperalgesia and potentiates morphine effects in the chronic constriction injury model of neuropathic pain. Eur J Pharmacol 2012;674:260–4. 10.1016/j.ejphar.2011.11.026
    1. Dogrul A, Gardell LR, Ossipov MH, et al. . Reversal of experimental neuropathic pain by T-type calcium channel blockers. Pain 2003;105:159–68. 10.1016/S0304-3959(03)00177-5
    1. Matthews EA, Dickenson AH. Effects of ethosuximide, a T-type Ca(2+) channel blocker, on dorsal horn neuronal responses in rats. Eur J Pharmacol 2001;415:141–9. 10.1016/S0014-2999(01)00812-3
    1. Okubo K, Takahashi T, Sekiguchi F, et al. . Inhibition of T-type calcium channels and hydrogen sulfide-forming enzyme reverses paclitaxel-evoked neuropathic hyperalgesia in rats. Neuroscience 2011;188:148–56. 10.1016/j.neuroscience.2011.05.004
    1. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain 2004;109:150–61. 10.1016/j.pain.2004.01.029
    1. Munro G, Erichsen HK, Mirza NR. Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety. Neuropharmacology 2007;53:609–18. 10.1016/j.neuropharm.2007.07.002
    1. Kawabata A, Ishiki T, Nagasawa K, et al. . Hydrogen sulfide as a novel nociceptive messenger. Pain 2007;132:74–81. 10.1016/j.pain.2007.01.026
    1. Barton M, Eberle E, Shannon H. The antihyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione, and mibefradil. Eur J Pharmacol . European journal of pharmacology 2005;85:79 10.1016/j.ejphar.2005.08.017
    1. Shannon HE, Eberle EL, Peters SC. Comparison of the effects of anticonvulsant drugs with diverse mechanisms of action in the Formalin test in rats. Neuropharmacology 2005;48:1012–20. 10.1016/j.neuropharm.2005.01.013
    1. Chen W-K, Liu I, Chang Y-T, et al. . Ca(v)3.2 T-type Ca2+ channel-dependent activation of ERK in paraventricular thalamus modulates acid-induced chronic muscle pain. J Neurosci 2010;8:10360 10.1523/JNEUROSCI.1041-10.2010
    1. Todorovic SM, Rastogi AJ, Jevtovic-Todorovic V. Potent analgesic effects of anticonvulsants on peripheral thermal nociception in rats. Br J Pharmacol 2003;140:255–60. 10.1038/sj.bjp.0705434
    1. Matsunami M, Kirishi S, Okui T, et al. . Hydrogen sulfide-induced colonic mucosal cytoprotection involves T-type calcium channel-dependent neuronal excitation in rats. J Physiol Pharmacol 2012;63:61–8.
    1. Sekiguchi F, Aoki Y, Nakagawa M, et al. . AKAP-dependent sensitization of Ca(v) 3.2 channels via the EP (4) receptor/cyclic AMP pathway mediates prostaglandin E (2) -induced mechanical hyperalgesia. Br J Pharmacol (Published Online First: 24 August 2012).
    1. Xu GY, Winston JH, Shenoy M, et al. . The endogenous hydrogen sulfide producing enzyme cystathionine-beta synthase contributes to visceral hypersensitivity in a rat model of irritable bowel syndrome. Mol Pain 2009;5:44 10.1186/1744-8069-5-44
    1. Li L, Xie R, Hu S, et al. . Upregulation of cystathionine beta-synthetase expression by nuclear factor-kappa B activation contributes to visceral hypersensitivity in adult rats with neonatal maternal deprivation. Mol Pain 2012;8:1744-8069-8-89 10.1186/1744-8069-8-89
    1. Maeda Y, Aoki Y, Sekiguchi F, et al. . Hyperalgesia induced by spinal and peripheral hydrogen sulfide: evidence for involvement of Cav3.2 T-type calcium channels. Pain 2009;142:127–32. 10.1016/j.pain.2008.12.021
    1. Sekiguchi F, Miyamoto Y, Kanaoka D, et al. . Endogenous and exogenous hydrogen sulfide facilitates T-type calcium channel currents in Cav3.2-expressing HEK293 cells. Biochem Biophys Res Commun 2014;445:225–9. 10.1016/j.bbrc.2014.01.185
    1. Müller-Lissner S, Koch G, Talley NJ, et al. . Subject's Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. J Clin Epidemiol 2003;56:310–6. 10.1016/S0895-4356(03)00027-1
    1. Eypasch E, Williams JI, Wood-Dauphinee S, et al. . Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. Br J Surg 1995;82:216–22. 10.1002/bjs.1800820229
    1. Bushnell DM, Martin ML, Ricci JF, et al. . Performance of the EQ-5D in patients with irritable bowel syndrome. Value Health 2006;9:90–7. 10.1111/j.1524-4733.2006.00086.x
    1. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395–402. 10.1046/j.1365-2036.1997.142318000.x
    1. Sarver JG, Bachmann KA, Zhu D, et al. . Ethosuximide is primarily metabolized by CYP3A when incubated with isolated rat liver microsomes. Drug Metab Dispos 1998;26:78–82.
    1. van der Weide J, Hinrichs JW. The influence of cytochrome P450 pharmacogenetics on disposition of common antidepressant and antipsychotic medications. Clin Biochem Rev 2006;27:17–25.
    1. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138:103–41. 10.1016/j.pharmthera.2012.12.007
    1. Ford AC, Quigley EM, Lacy BE, et al. . Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2014;109:1350–65. 10.1038/ajg.2014.148
    1. Vickers AJ, Altman DG. Statistics notes: Analysing controlled trials with baseline and follow up measurements. BMJ 2001;323:1123–4. 10.1136/bmj.323.7321.1123

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever